Here's what we'll cover
Here's what we'll cover
Medicare Finally Opened a Door for GLP-1 Weight Loss Drugs, but Not for Everyone
For years, Medicare Part D was barred from paying for drugs used purely for weight loss. That changed on July 1, 2026, when the Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge, a temporary demonstration that lets eligible beneficiaries fill certain GLP-1 weight loss medications for a flat $50 copay per month.
For many older adults, that is a dramatic drop from list prices that once topped $1,000 a month. But the program has tight clinical rules and some exclusions that surprise people, including a group you might assume would qualify first: people with type 2 diabetes.
This guide explains how the Bridge works, exactly who is eligible, who is left out and why, and what your options are if you fall outside the lines.
What the Medicare GLP-1 Bridge Actually Is
The Bridge is a CMS demonstration that runs from July 1, 2026 through December 31, 2027. It was first planned to last only six months, but CMS extended it after it postponed the larger BALANCE model for Part D, according to AARP and the CMS program page.
A few structural details matter for patients:
- It operates outside your normal Part D benefit. A single central processor handles prior authorization, claims, and pharmacy payment, not your Part D plan.
- The copay is $50 per eligible prescription for a 28 or 30 day supply.
- The Part D deductible does not apply, but the $50 copays also do not count toward the 2026 Part D out of pocket cap of $2,100.
- Low income subsidy (Extra Help) does not reduce the Bridge copay, and manufacturer coupons cannot be layered on top, per GoodRx clinical guidance.
Which Medications Are Covered
The Bridge covers a short list of drugs approved for chronic weight management:
- Wegovy injections and Wegovy tablets (oral semaglutide)
- Foundayo (orforglipron) tablets
- Zepbound (tirzepatide) KwikPen
Zepbound single dose pens and vials are not included. Diabetes brands such as Ozempic and Mounjaro are not part of the Bridge because they already have a Part D pathway for type 2 diabetes.
Who Qualifies for the $50 Copay
You must be at least 18, enrolled in Medicare Part D through a standalone prescription drug plan or an eligible Medicare Advantage plan with drug coverage, and prescribed the drug to reduce excess weight and maintain weight loss. At the start of treatment you must also meet one of three clinical thresholds:
| BMI at start of treatment | Additional requirement |
|---|---|
| 35 or higher | None |
| 30 or higher | Stage 3a or higher chronic kidney disease, heart failure with preserved ejection fraction, or uncontrolled high blood pressure despite two medications |
| 27 or higher | Prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease |
KFF has estimated that roughly 3.8 million Medicare beneficiaries could meet these criteria, as reported by AARP.
Who Does Not Qualify and Why
The exclusions are where most of the confusion comes from. Several groups are shut out of the $50 copay even if their BMI fits.
People With Type 2 Diabetes
Beneficiaries with type 2 diabetes are not eligible for the Bridge, even if they meet the BMI criteria. The logic from CMS is that these patients already have a route to GLP-1 therapy through their regular Part D plan, where drugs like Ozempic, Mounjaro, and Rybelsus are covered for diabetes. The catch is that Part D cost sharing for those drugs can be far higher than $50 a month, especially early in the year, so some diabetic patients end up paying more than their non diabetic neighbors.
People With Obstructive Sleep Apnea or MASH
Patients with obstructive sleep apnea or metabolic dysfunction associated steatohepatitis (MASH) are also excluded. Again, CMS points to existing Part D pathways, since Zepbound carries an FDA indication for sleep apnea and Wegovy has an indication for MASH. Coverage for those uses runs through your plan's formulary, prior authorization, and normal cost sharing.
People Taking GLP-1s for Heart Protection
Since the FDA approved Wegovy in 2024 to reduce the risk of major cardiovascular events, based on the SELECT trial, Part D plans can cover it for that indication. Beneficiaries prescribed a GLP-1 to lower heart attack or stroke risk, rather than for weight reduction, must use their Part D plan, not the Bridge, per the FDA approval announcement and program rules summarized by AARP.
People Who Miss the Clinical Thresholds
Someone with a BMI of 32 and no listed comorbidity, or a BMI of 28 with high blood pressure that is controlled on medication, does not meet the criteria. Conditions like osteoarthritis or high cholesterol, while weight related, are not on the qualifying list.
People Without the Right Drug Coverage
Beneficiaries with Original Medicare and no Part D plan cannot use the Bridge. PACE enrollees qualify only if they also have a standalone Part D plan. Patients who want a non covered product, such as Zepbound vials, will not get the $50 price on that product.
How the Prior Authorization Process Works
Your prescriber does not need to be enrolled in Medicare, but cannot be on the Medicare preclusion list. The steps, as outlined in GoodRx's clinician guide and the CMS FAQ document, look like this:
- Your prescriber sends a 28 or 30 day prescription to the pharmacy with an obesity diagnosis code (E66) and asks that the claim go to the Bridge rather than your Part D plan.
- The prescriber submits the Bridge prior authorization form electronically or by fax.
- CMS targets a decision within 72 hours, and you receive the result by mail.
- Once approved, refills of the same drug do not need a new authorization. Switching to a different covered drug does.
If you are denied, the request can be corrected and resubmitted. Questions go to 1-800-MEDICARE, not your Part D plan.
What to Do If You Do Not Qualify
Ask Exactly Why
Many denials come down to paperwork: a missing diagnosis code, an outdated BMI, or a comorbidity that is not documented. Ask your prescriber to review whether your chart accurately reflects conditions like prediabetes, chronic kidney disease, or uncontrolled blood pressure.
Use Your Part D Plan for Diabetes, Sleep Apnea, MASH, or Heart Risk
If you were excluded because you have one of those conditions, your path is your own Part D plan. Check your plan's formulary for Ozempic, Mounjaro, Wegovy, or Zepbound, ask about prior authorization requirements, and remember that in 2026 your total Part D out of pocket spending is capped at $2,100.
Compare Self Pay Prices
Manufacturer cash prices have fallen. Novo Nordisk and Eli Lilly both sell certain weight loss products directly, with starting doses of the newer oral options priced at about $149 a month. Medicare beneficiaries can generally pay cash outside their insurance, though those payments will not count toward Part D limits. Review current GLP-1 coupons and savings programs and talk with your prescriber before choosing this route.
Get Free Counseling
Your State Health Insurance Assistance Program offers free, unbiased Medicare counseling and can help you compare Part D plans during open enrollment, which runs from October 15 to December 7.
Questions to Ask Your Doctor
- Do I meet one of the three Bridge BMI thresholds based on my most recent measurements?
- Are all of my qualifying conditions, such as prediabetes or kidney disease, documented in my chart?
- If I have type 2 diabetes, sleep apnea, or MASH, which GLP-1 does my Part D plan cover and what will it cost me?
- Should I use Wegovy, Foundayo, or the Zepbound KwikPen, given what the Bridge covers?
- What is our plan if the Bridge ends after December 2027?
No waiting list. No insurance needed.
Frequently Asked Questions
What is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a CMS demonstration running from July 1, 2026 through December 31, 2027 that lets eligible Part D enrollees fill certain GLP-1 weight loss drugs for a $50 monthly copay. It operates outside the normal Part D benefit, with a central processor handling prior authorization and claims.
Which drugs does the Medicare GLP-1 Bridge cover?
The Bridge covers Wegovy injections and tablets, Foundayo (orforglipron) tablets, and the Zepbound KwikPen. Zepbound vials and single dose pens are not included, and diabetes brands like Ozempic and Mounjaro are not part of the program.
Why are people with type 2 diabetes excluded from the Bridge?
CMS excludes beneficiaries with type 2 diabetes because they already have access to GLP-1 drugs through their regular Part D plan, where medications like Ozempic and Mounjaro are covered for diabetes. Their cost sharing follows the plan's normal rules, which can be higher than $50 a month.
What BMI do I need to qualify for the $50 copay?
You need a BMI of 35 or higher, or 30 or higher with stage 3a or higher kidney disease, heart failure with preserved ejection fraction, or uncontrolled hypertension, or 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
Do Bridge copays count toward the Part D out of pocket cap?
No. The $50 Bridge copays do not count toward the 2026 Part D out of pocket cap of $2,100, and the Part D deductible does not apply. Extra Help does not lower the Bridge copay, and manufacturer coupons cannot be combined with it.
Can I use the Bridge if I only have Original Medicare?
No. You must be enrolled in a standalone Part D prescription drug plan or an eligible Medicare Advantage plan with drug coverage. PACE enrollees qualify only if they also have a standalone Part D plan.
The Bottom Line
The Medicare GLP-1 Bridge is the first real crack in Medicare's long standing ban on weight loss drugs, and for eligible beneficiaries a $50 monthly copay is a meaningful change. But it is a temporary demonstration with narrow clinical criteria, and it deliberately excludes people whose conditions already have a Part D pathway, including type 2 diabetes, sleep apnea, and MASH.
If you are on Medicare, start by confirming whether you fit one of the three BMI tiers. If you do not, work with your doctor to confirm your chart is complete, check what your Part D plan covers, and compare cash prices. The program is currently scheduled to end on December 31, 2027, and CMS has said the paused BALANCE model could still return, so use the fall 2027 open enrollment period to plan for continuity.
For help finding a prescriber who can manage prior authorizations, compare vetted telehealth providers. And always talk with your physician before starting, stopping, or switching any GLP-1 medication.